recommend
treatment
chronic
hepat
b
andor
nucleo
ide
analogu
lead
satisfactori
result
induct
hbvspecif
cell
therapeut
vaccin
immunotherapi
may
innov
strategi
overcom
viru
persist
vaccin
commerci
avail
hbv
vaccin
patient
result
effect
control
hbv
infect
suggest
new
formul
therapeut
vaccin
need
woodchuck
marmota
monax
use
preclin
model
develop
new
therapeut
approach
chronic
hepadnavir
infect
sever
innov
approach
combin
antivir
treatment
nucleo
ide
analogu
dna
vaccin
protein
vaccin
test
woodchuck
model
paper
summar
avail
data
concern
therapeut
immun
gene
therapi
use
recombin
viral
vector
approach
woodchuck
show
encourag
result
addit
present
potenti
innov
immunomodulatori
strategi
evalu
anim
model
world
health
organ
estim
billion
peopl
worldwid
infect
hepat
b
viru
hbv
sinc
introduct
prevent
vaccin
program
hepat
b
countri
number
new
infect
continu
decreas
despit
success
prophylact
vaccin
chronic
hbv
infect
still
global
health
problem
million
peopl
persist
infect
hbv
million
die
year
hbvassoci
liver
cirrhosi
hepatocellular
carcinoma
hcc
outcom
hbv
infect
vari
greatli
person
person
case
infect
clear
spontan
howev
adult
develop
chronic
infect
contrast
children
born
hbvinfect
mother
progress
develop
persist
liver
diseas
recent
year
mark
progress
made
treatment
chronic
hepat
b
current
two
type
antivir
therapi
approv
treatment
pegyl
interferon
alpha
nucleo
ide
analogu
adefovir
entecavir
etv
lamivudin
telbivudin
tenofovir
howev
efficaci
therapi
prevent
liver
cirrhosi
hcc
still
limit
treatment
lead
sustain
antivir
respons
one
third
patient
regardless
combin
therapi
polymeras
inhibitor
hand
treatment
nucleo
ide
analogu
significantli
suppress
hbv
replic
lead
decreas
necroinflamm
liver
howev
antivir
complet
erad
viru
withdraw
drug
rebound
viremia
observ
major
patient
furthermor
longterm
treatment
subsequ
associ
appear
drugresist
hbv
strain
often
caus
therapi
failur
therefor
new
approach
treat
chronic
hepat
b
urgent
need
well
document
appropri
adapt
immun
respons
requir
effici
control
hbv
infect
cellmedi
immun
respons
direct
hepat
research
treatment
hepat
b
viru
antigen
crucial
resolut
infect
hbvspecif
cell
abl
clear
hbvinfect
hepatocyt
secret
antivir
cytokin
interferon
ifn
tumor
necrosi
factor
alpha
direct
cytotox
mechan
perforingranzym
ligandligand
induc
cell
death
eg
fasfasl
earli
vigor
polyclon
multispecif
cellular
immun
respons
viral
protein
associ
clearanc
hepat
b
acutelyinfect
patient
contrast
chronic
hbv
carrier
demonstr
weak
transient
often
undetect
cell
respons
correl
hbv
persist
humor
immun
respons
especi
neutral
antienvelop
antibodi
play
key
role
prevent
hbv
spread
noninfect
hepatocyt
recent
studi
indic
sever
mechan
may
involv
loss
function
hbvspecif
cell
chronic
hepat
b
shown
highlevel
viremia
neg
influenc
virusspecif
immun
respons
high
viral
replic
liver
viral
load
higher
copiesml
correl
hyporespons
virusspecif
cell
patient
chronic
hepat
b
moreov
prolong
exposur
viral
antigen
occur
chronic
viral
infect
trigger
cell
becom
toler
prone
apoptosi
interact
program
death
receptor
ligand
also
known
play
import
role
prevent
overreact
immun
system
recent
studi
reveal
inhibitori
molecul
markedli
upregul
virusspecif
cell
result
exhaust
eg
lack
product
prolifer
simultan
mechan
contribut
develop
chronic
infect
impair
effect
antivir
respons
hypothesi
previous
proven
hepat
c
viru
hcv
human
immunodefici
viru
hiv
infect
human
well
lymphocyt
choriomening
viru
lcmv
infect
mice
recent
hbv
furthermor
sever
studi
impli
function
defect
antigen
present
cell
apc
mainli
dendrit
cell
dc
may
contribut
impair
cell
respons
chronic
hepat
b
patient
vitro
studi
show
dc
isol
hbv
chronic
carrier
produc
lower
amount
antivir
cytokin
type
interferon
comparison
healthi
control
addit
dc
less
effici
cell
activ
stimul
cell
prolifer
novel
report
demonstr
myeloid
dc
chronic
hbv
patient
express
increas
level
inhibitori
molecul
therefor
may
regul
function
hbvspecif
cell
sever
investig
underlin
signific
regulatori
cell
pathogenesi
persist
viral
infect
hcvand
hivinfect
patient
shown
regulatori
cell
may
downregul
hcvand
hivspecif
therefor
influenc
diseas
progress
role
regulatori
cell
hbv
infect
still
clear
nevertheless
increas
number
regulatori
cell
detect
blood
liver
patient
chronic
sever
hepat
b
addit
liver
organ
tolerogen
properti
might
contribut
immunolog
toler
chronic
hbv
infect
final
virus
develop
strategi
effici
evad
host
immun
respons
result
persist
infect
viral
immun
escap
due
mutat
b
cell
epitop
given
hla
background
observ
patient
infect
hiv
hcv
hbv
sever
studi
demonstr
treatment
lamivudin
alon
combin
result
restor
hbvspecif
immun
respons
chronic
hbvinfect
individu
howev
therapeut
effect
sustain
patient
year
continu
effort
undertaken
develop
therapeut
vaccin
chronic
hepat
b
enhanc
virusspecif
immun
respons
overcom
persist
hbv
infect
numer
clinic
trial
therapeut
immun
exploit
convent
prophylact
hepat
b
surfac
antigen
hbsag
base
protein
vaccin
studi
demonstr
reduct
viremia
hbeagantihb
seroconvers
hbvspecif
cell
respons
patient
howev
antivir
effect
transient
lead
effect
control
hbv
combin
hbsag
protein
vaccin
antivir
treatment
lamivudin
lead
satisfactori
improv
therapi
strategi
design
specif
stimul
hbvspecif
cell
respons
also
success
lipopeptidebas
vaccin
contain
singl
cytotox
lymphocyt
ctl
epitop
deriv
hbv
nucleocapsid
abl
induc
vigor
primari
hbvspecif
cell
respons
subject
howev
hbv
chronic
carrier
vaccin
initi
poor
ctl
activ
effect
viremia
hbeagantihb
seroconvers
dna
vaccin
express
small
middl
envelop
protein
prove
elicit
hbvspecif
cellular
immun
respons
chronic
hbv
carrier
howev
effect
transient
yang
et
al
present
novel
dna
vaccin
treatment
chronic
hepat
combin
immun
lamivudin
treatment
multigen
vaccin
contain
five
differ
plasmid
encod
hbv
antigen
human
gene
genet
adjuv
combin
therapi
led
sustain
antivir
respons
hbv
chronic
infect
patient
respond
abl
clear
hbeag
undetect
viral
load
end
followup
effect
correl
detect
cell
respons
least
one
hbv
antigen
nevertheless
studi
need
evalu
strategi
larger
cohort
hbv
chronic
carrier
therapeut
vaccinebas
hbsag
complex
human
antihb
propos
group
wen
et
al
immunogen
complex
ic
stimul
robust
cell
respons
increas
uptak
hbsag
fc
receptor
apc
therefor
modul
hbsag
process
present
demonstr
vaccin
administ
hbeagposit
patient
led
decreas
hbv
dna
serum
hbeag
seroconvers
develop
antihb
part
subject
current
icbas
vaccin
one
enter
phase
iii
clinic
trial
chronic
hepat
b
patient
even
though
icbas
vaccin
led
antivir
effect
clearanc
hbv
observ
treat
patient
seem
vaccin
alon
suffici
achiev
full
control
hbv
therefor
step
undertaken
combin
icbas
vaccin
nucleo
ide
analogu
treatment
wen
et
al
person
commun
ongo
clinic
trial
show
whether
ic
effect
therapeut
vaccin
chronic
hepat
b
year
variou
anim
model
includ
chimpanze
woodchuck
duck
hbv
transgen
mice
establish
develop
evalu
novel
therapeut
strategi
consid
cost
ethic
reason
avail
amount
hbv
transgen
mice
wide
use
model
studi
use
hbv
transgen
mous
model
demonstr
dna
immun
express
plasmid
encod
differ
hbv
protein
could
induc
hbvspecif
antibodi
stimul
ctl
respons
howev
function
hbvspecif
ctl
induc
transgen
mice
may
fulli
develop
improv
dna
vaccin
regimen
blockad
interact
could
enhanc
function
cell
respons
lead
inhibit
viral
replic
vivo
without
caus
hepat
apart
dna
immun
therapeut
approach
includ
administr
tolllik
receptor
tlr
ligand
hbvspecif
sirna
direct
activ
apc
evalu
hbv
transgen
mice
strategi
abl
effect
reduc
hbv
replic
current
investig
combin
therapi
nevertheless
model
signific
limit
hbv
genom
insert
mous
chromosom
full
hbv
life
cycl
take
place
transgen
mice
liver
inflamm
observ
thu
anim
model
natur
occur
hepadnavir
infect
requir
longterm
evalu
therapeut
effect
comparison
chimpanze
woodchuck
easili
avail
afford
paper
would
like
introduc
woodchuck
use
preclin
model
design
new
therapeut
vaccin
chronic
hepadnavir
infect
summar
avail
data
concern
therapeut
immun
approach
woodchuck
present
potenti
innov
immunomodulatori
strategi
yet
evalu
anim
model
eastern
woodchuck
marmota
monax
natur
infect
woodchuck
hepat
viru
whv
whv
discov
viru
close
relat
hbv
classifi
member
hepadnavirida
famili
whv
hbv
show
mark
similar
virion
structur
genom
organ
mechan
replic
differ
sever
aspect
exampl
regul
transcript
tabl
whv
caus
acut
selflimit
chronic
infect
similar
hbv
infect
pathogenesi
profil
virusspecif
immun
respons
featur
woodchuck
model
make
signific
investig
new
therapeut
approach
chronic
hepat
b
experiment
infect
neonat
adult
woodchuck
whv
reflect
outcom
hbv
infect
human
adult
woodchuck
infect
whv
usual
lead
resolut
infect
anim
develop
chronic
hepat
exposur
woodchuck
neonat
whv
result
develop
chronic
whv
infect
case
continu
replic
whv
liver
chronic
infect
nearli
alway
associ
develop
hcc
woodchuck
diagnosi
hcc
surviv
prognosi
anim
estim
month
like
human
common
featur
hbvand
whvinduc
carcinogenesi
give
opportun
examin
new
antihcc
therapi
woodchuck
mani
year
studi
immunopathogenesi
whv
infect
woodchuck
restrict
determin
humor
immun
respons
lack
appropri
method
evalu
antigenspecif
cell
respons
seriou
limit
model
prolifer
assay
peripher
blood
mononuclear
cell
pbmc
base
incorpor
h
thymidin
cellular
dna
routin
use
human
mous
system
ineffect
woodchuck
pbmc
failur
approach
consist
fact
woodchuck
lymphocyt
express
thymidin
kinas
gene
menn
et
al
unpublish
result
obstacl
overcom
usag
altern
radioact
label
nucleotid
h
adenin
develop
h
adeninebas
prolifer
assay
enabl
detect
thelper
lymphocyt
respons
stimul
woodchuck
pbmc
whv
core
surfac
x
antigen
whcag
whsag
whxag
resp
addit
use
h
adeninebas
prolifer
assay
pbmc
acut
infect
anim
sever
thelper
epitop
within
whcag
whsag
identifi
menn
et
al
unpublish
result
recent
establish
novel
degranul
assay
woodchuck
pbmc
splenocyt
made
signific
breakthrough
studi
pathogenesi
hapadnavir
infect
woodchuck
model
sever
studi
demonstr
detect
degranul
marker
suitabl
method
determin
antigen
hepat
research
treatment
surfac
glycoprotein
largel
mediumm
small
core
protein
x
protein
e
antigen
dna
polymeras
reversetranscriptas
activ
correspond
protein
replic
strategi
replic
hbv
dna
occur
revers
transcript
rna
intermedi
within
cytoplasm
nucleocapsid
mechan
genet
divers
major
genotyp
major
genotyp
minor
sequenc
differ
integr
host
chromosom
ye
ye
often
close
nmyc
oncogen
region
clinic
cours
infect
character
figur
contrast
selflimit
infect
whv
chronic
carrier
demonstr
weak
virusspecif
cell
respons
identifi
epitop
establish
assay
monitor
cellular
immun
respons
woodchuck
great
import
reliabl
evalu
therapeut
immunomodulatori
strategi
treatment
chronic
hepat
b
woodchuck
model
recent
describ
advanc
character
monitor
woodchuck
immun
system
whv
infect
made
anim
model
particularli
use
develop
immunomodulatori
approach
chronic
hepat
b
natur
occurr
chronic
whv
infect
woodchuck
close
relat
hbv
infect
human
allow
evalu
potenti
new
therapeut
strategi
directli
chronic
whv
carrier
date
sever
studi
divers
therapeut
vaccin
carri
woodchuck
tabl
pioneer
investig
base
therapeut
vaccin
base
whv
core
surfac
antigen
combin
helper
peptid
fi
potent
adjuv
like
monophosphoryl
lipid
lead
satisfactori
result
experi
prove
vaccin
could
induc
specif
bandor
cell
respons
chronic
whv
carrier
howev
alon
suffici
achiev
control
viru
replic
assum
high
level
viremia
chronic
hepat
b
inhibit
therapeut
effect
vaccin
treatment
chronic
hbv
patient
lamivudin
could
transient
restor
hbvspecif
cell
immun
respons
therefor
reduct
viral
load
nucleo
ide
analogu
pretreat
might
support
efficaci
immun
enhanc
virusspecif
immun
respons
hypothesi
test
three
experiment
trial
combin
therapi
chronic
whv
carrier
first
studi
perform
et
al
base
lamivudin
therapi
five
chronic
whvinfect
woodchuck
treat
oral
drug
week
week
declin
whv
dna
log
three
anim
vaccin
dose
serumpurifi
whsag
combin
thelper
fi
peptid
deriv
sperm
whale
myoglobin
vaccin
induc
thelper
respons
whv
antigen
shift
cytokin
profil
howev
benefici
effect
whv
viral
load
whsag
level
observ
comparison
nonimmun
anim
withdraw
lamivudin
treatment
valu
viremia
return
pretreat
level
second
trial
evalu
therapi
potent
antivir
drug
clevudin
previous
call
lfmau
combin
whsagbas
immun
larg
cohort
thirti
chronic
whvinfect
woodchuck
enrol
studi
half
anim
oral
treat
clevudin
mgkgday
week
woodchuck
receiv
placebo
withdraw
clevudin
treatment
anim
group
vaccin
four
dose
formalin
inactiv
alumadsorb
whsag
inject
salin
control
combin
drug
vaccin
therapi
result
mark
reduct
whv
dna
log
whsag
serum
monitor
period
contrast
vaccin
placebo
group
marker
remain
high
level
combin
therapi
enhanc
antiwh
respons
beyond
measur
vaccin
alon
howev
treatment
clevudin
vaccin
togeth
led
sustain
robust
lymphoprolif
respons
whsag
addit
whcag
wheag
whxag
moreov
combin
therapi
delay
onset
liver
diseas
prevent
hcc
develop
treat
chronic
whv
carrier
longterm
followup
studi
recent
novel
therapeut
approach
treatment
chronic
hepat
b
woodchuck
model
describ
therapi
combin
antivir
treatment
immun
plasmid
dna
antigenantibodi
immunogen
complex
vaccin
togeth
dna
vaccin
consid
stimul
humor
cellular
immun
respons
polar
cell
direct
respons
immun
woodchuck
plasmid
encod
whv
core
gene
pwhcim
pwhsim
resp
induc
lymphoprolif
respons
antigen
provid
protect
whv
challeng
addit
dna
vaccin
express
hbsag
prove
elicit
vigor
cell
respons
chronic
hbv
carrier
howev
effect
transient
hbsagantihb
ic
vaccin
current
investig
chronic
hbv
patient
evalu
efficaci
previous
mention
immunotherapi
woodchuck
firstli
chronic
whv
carrier
treat
mg
lamivudin
daili
week
week
four
anim
pretreat
cardiotoxin
receiv
three
immun
dna
vaccin
contain
three
plasmid
express
whsag
whcag
woodchuck
pwhsim
pwhcim
pwifn
resp
simultan
four
woodchuck
receiv
three
dose
combin
dna
vaccin
whsagantiwh
immunogen
complex
two
chronic
whv
carrier
serv
lamivudin
monotherapi
control
lamivudin
treatment
result
slight
decreas
whv
dna
level
woodchuck
serum
log
resp
surprisingli
dna
vaccin
lead
addit
therapeut
effect
beyond
observ
lamivudin
treatment
alon
contrast
tripl
combin
antivir
treatment
plasmid
dna
encod
whcag
whsag
ic
vaccin
abl
decreas
whv
viral
load
log
serum
whsag
moreov
three
four
treat
anim
develop
antiwh
antibodi
nevertheless
effect
sustain
paramet
reach
baselin
level
shortli
withdraw
lamivudin
treatment
addit
vaccin
induc
whvspecif
cell
respons
major
woodchuck
even
anim
exhibit
virolog
respons
signific
hepat
research
treatment
lymphoprolif
respons
whv
antigen
detect
one
anim
three
immun
dna
vaccin
studi
demonstr
benefit
use
combinatori
therapi
chronic
whvinfect
woodchuck
howev
transient
therapeut
effect
suggest
strategi
need
optim
result
previou
studi
clearli
confirm
poor
efficaci
lamivudin
therapi
woodchuck
new
strategi
evalu
potenc
entecavir
treatment
increas
number
immun
lu
et
al
unpublish
result
chronic
whvinfect
woodchuck
pretreat
entecavir
week
week
daili
week
weekli
manner
weekli
administr
drug
one
group
anim
receiv
immun
twoplasmid
dna
vaccin
pwhsim
pwhcim
second
group
receiv
combin
dna
vaccin
togeth
purifi
whv
core
surfac
antigen
third
group
remain
untreat
entecavir
therapi
result
rapid
signific
decreas
viral
load
whsag
level
serum
anim
effect
especi
pronounc
anim
addit
receiv
vaccin
woodchuck
treat
entecavir
increas
viremia
observ
alreadi
weekli
administr
immedi
withdraw
drug
contrast
group
anim
immun
dna
dnaprotein
vaccin
delay
rebound
whv
replic
significantli
prolong
addit
entecavir
treatment
effect
suppress
whv
replic
enhanc
induct
whvspecif
cell
respons
increas
ctl
activ
detect
individu
woodchuck
dna
dnaprotein
vaccin
moreov
two
anim
complet
elimin
viru
blood
whv
dna
neg
liver
lu
et
al
unpublish
result
altogeth
result
obtain
woodchuck
model
concern
combin
nucleot
ide
therapi
immun
prove
synergist
effect
therapeut
approach
therapeut
effect
observ
therapi
significantli
increas
prolong
comparison
monotherapi
alon
addit
therapeut
approach
could
stimul
whvspecif
cell
respons
usual
impair
whv
chronic
carrier
combin
antivir
treatment
vaccin
requir
improv
viru
specif
cell
respons
design
futur
therapeut
approach
includ
pretreat
potent
antivir
drug
entecavir
clevudin
prove
efficaci
woodchuck
model
previou
result
therapeut
immun
trial
woodchuck
chimpanze
human
indic
licens
vaccin
abl
boost
function
antivir
cell
respons
need
use
potent
strategi
vaccin
base
recombin
virus
gain
great
interest
abil
stimul
robust
humor
cellular
immun
respons
viral
vector
investig
prophylact
therapeut
vaccin
mani
human
pathogen
measl
viru
herp
simplex
viru
hsv
human
papillomaviru
hpv
hiv
rabi
howev
util
recombin
vaccin
treatment
chronic
hepat
b
yet
evalu
preliminari
result
obtain
studi
chronic
hbvinfect
chimpanze
immun
retrovir
vector
base
moloney
murin
leukemia
viru
encod
hbcag
suggest
investig
viralvector
base
vaccin
taken
consider
experi
one
three
therapeut
immun
chronic
carrier
chimpanze
clear
viru
show
hbeag
seroconvers
signific
alt
elev
observ
anim
implic
restor
hbvspecif
cytotox
humor
respons
without
caus
fulmin
hepat
moreov
two
chimpanze
demonstr
high
antihb
titer
therapi
one
hbcagspecif
ctl
studi
demonstr
benefit
use
recombin
viralvector
treatment
chronic
hbv
infect
primat
model
also
possibl
advantag
use
core
antigenbas
therapeut
vaccin
even
though
retrovir
vector
vaccin
well
toler
chimpanze
sever
clinic
trial
suggest
gene
therapi
tradit
retrovir
vector
lead
oncogenesi
therefor
usag
anoth
recombin
viru
carrier
protein
could
benefici
recombin
adenovirus
one
intens
investig
viral
vector
therapeut
purpos
develop
novel
method
manipul
viral
genom
result
three
gener
recombin
adenovirus
increas
capac
figur
sever
trial
impli
use
vector
gene
therapi
genet
diseas
cancer
mani
year
first
gener
replicationdefici
adenovir
vector
explor
vaccin
carrier
prevent
infecti
diseas
adenovir
vector
sever
advantag
benefici
potent
therapeut
vaccin
first
adenovirus
rel
suscept
genet
modif
easili
produc
high
titer
transduct
cell
adenovir
genom
integr
host
dna
stay
episom
form
result
risk
possibl
activ
cellular
oncogen
minim
adenovirusbas
vaccin
prove
elicit
vigor
sustain
humor
cell
respons
incorpor
antigen
consid
crucial
clearanc
persist
viral
diseas
benefit
adenovir
vector
vaccin
carrier
limit
stabl
deliveri
protein
interest
sever
find
addit
immunostimulatori
effect
exampl
induct
innat
immun
respons
origin
natur
adenovirus
may
enhanc
vaccin
efficaci
capsid
adenovirus
demonstr
immunostimulatori
properti
coadministr
adjuv
usual
unnecessari
vector
directli
transduc
dc
caus
matur
upregul
mhc
costimulatori
molecul
surfac
thu
lead
enhanc
antigen
present
moreov
shown
advtransduc
dc
secret
antivir
cytokin
one
import
factor
suppress
function
regulatori
cell
nevertheless
modifi
adenovirus
apart
abovement
advantag
one
seriou
limit
thu
far
vector
comprehens
examin
vaccin
base
human
adenoviru
serotyp
serotyp
common
human
popul
neutral
antibodi
detect
adult
preexist
immun
direct
consid
main
reason
failur
phase
clinic
trial
protect
vaccin
step
studi
guid
merck
pharmaceut
concern
base
regimen
trival
vaccin
suggest
immun
might
increas
risk
infect
subject
high
neutral
titer
moreov
even
singl
immun
may
induc
immun
vector
seroneg
individu
neg
effect
preexist
immun
vaccin
mostli
therapi
requir
multipl
dosag
may
overcom
heterolog
primeboost
regimen
util
rare
human
serotyp
eg
serotyp
recombin
adenovirus
nonhuman
origin
recent
test
particular
subsequ
prime
immun
plasmid
dna
vaccin
follow
booster
vaccin
adv
seem
promis
strategi
dna
primeadenoviru
boost
regimen
prove
induc
robust
potent
immun
respons
comparison
plasmid
dna
alon
provid
protect
pathogen
challeng
sever
anim
model
infecti
diseas
furthermor
clinic
trial
multiclad
dna
boost
vaccin
hivuninfect
individu
demonstr
high
immunogen
even
presenc
high
antibodi
titer
addit
vaccin
prove
well
toler
particip
studi
sever
studi
indic
transgen
express
level
increas
adenovir
vector
presenc
insert
intron
sequenc
therefor
construct
new
recombin
adenovirus
serotyp
encod
whv
core
protein
contain
intron
promot
whcag
gene
sequenc
preliminari
experi
show
vaccin
adv
contain
intron
sequenc
led
induct
robust
cellular
humor
immun
respons
mice
moreov
immun
mice
dna
primeadv
boost
manner
use
improv
vector
result
vigor
multispecif
cell
respons
comparison
immun
plasmid
dna
alon
kosinska
et
al
unpublish
result
immun
chronic
whvinfect
woodchuck
plasmid
dna
vaccin
combin
entecavir
treatment
show
mark
therapeut
effect
addit
recombin
adenovirus
regimen
could
new
potent
approach
treatment
chronic
hepat
b
appli
dna
primeadv
boost
approach
whv
chronic
infect
woodchuck
combin
nucleo
ide
analog
evalu
therapeut
potenti
last
year
modifi
adenovirus
extens
studi
vehicl
gene
deliveri
liver
high
transfect
effici
natur
tropism
hepatocyt
moreov
develop
third
gener
adenovir
vector
lack
viral
code
sequenc
eg
helperdepend
adenovir
vector
result
increas
capac
minim
immunogen
vector
allow
longterm
transgen
express
high
clone
capac
vector
enabl
usag
induc
tissuespecif
promot
coexpress
multipl
therapeut
immunomodulatori
gene
far
sever
trial
virusmedi
gene
therapi
treatment
chronic
hepat
hcc
perform
chronic
whvinfect
woodchuck
cell
cultur
system
strategi
mainli
base
deliveri
antivir
cytokin
recombin
adenovirus
reduc
viral
replic
modul
immun
respons
tabl
transduct
primari
woodchuck
hepatocyt
chronic
whv
carrier
helperdepend
adv
encod
woodchuck
result
reduct
whv
protein
express
vitro
vivo
studi
chronic
whvinfect
woodchuck
demonstr
singl
inject
vp
vector
liver
portal
vein
could
inhibit
whv
replic
log
week
treatment
approach
helperdepend
adv
express
woodchuck
show
antivir
effect
even
though
transduct
led
product
biolog
activ
interferon
anoth
studi
combin
intraven
deliveri
recombin
adenovir
vector
nucleo
ide
analogu
therapi
chronic
whv
carrier
treat
clevudin
emtricitabin
ftc
togeth
week
initi
drop
viral
load
one
group
anim
receiv
addit
two
iv
inject
pfu
deliveri
induc
inflamm
caus
cell
infiltr
increas
hepatocyt
turnov
howev
effect
induc
addit
antivir
outcom
comparison
clevudineemtricitabin
biotherapi
alon
similarli
poor
therapeut
effect
observ
gene
therapi
base
intraven
inject
recombin
adenovirus
clevudin
treatment
led
decreas
replic
intermedi
whv
dna
liver
beyond
could
achiev
clevudin
alon
nevertheless
week
inject
signific
differ
group
whv
carrier
receiv
adv
express
cytokin
betagalactosidas
control
benefit
use
immunomodulatori
gene
studi
difficult
assess
sinc
report
adenoviru
infect
alon
suffici
transient
suppress
whv
replic
chronic
infect
woodchuck
lack
therapeut
effect
direct
deliveri
consist
vitro
data
obtain
persistentlyinfect
woodchuck
primari
hepatocyt
treatment
cell
even
presenc
abl
inhibit
whv
replic
moreov
high
concentr
cytokin
result
loss
cell
cultur
observ
underlin
cytotox
effect
cytokin
woodchuck
hepatocyt
rapid
downregul
express
transduct
liver
cell
viral
vector
could
one
mechan
protect
organ
potenti
toxic
cytokin
vivo
addit
sever
report
indic
level
higher
liver
chronic
whv
carrier
comparison
anim
therefor
continu
presenc
inflammatori
cytokin
liver
chronic
whv
infect
could
result
hyporespons
hepatocyt
therapi
novel
strategi
treat
chronic
whv
hepat
base
adenovirusmedi
deliveri
murin
gene
hepatocyt
proinflammatori
cytokin
produc
natur
antigen
present
cell
stimul
product
natur
killer
nk
cell
enhanc
cytotox
activ
studi
gene
express
could
regul
induc
promot
respond
progesteron
antagonist
eight
chronic
whv
carrier
receiv
singl
dose
iu
adv
express
intrahepat
inject
laparotomi
two
week
express
induc
administr
treatment
result
intens
sustain
suppress
whv
replic
liver
well
decreas
viral
load
serum
effect
howev
visibl
anim
basal
viremia
lower
whv
copi
per
millilit
serum
anim
respond
therapi
develop
vigor
cell
respons
whcag
measur
woodchuck
product
demonstr
wheag
whsag
seroconvers
moreov
level
liver
anim
decreas
nonrespond
woodchuck
valu
significantli
upregul
find
suggest
intrahepat
express
may
inhibit
regulatori
cell
liver
chronic
whv
infect
indirect
induct
inflammatori
cytokin
seem
effici
strategi
break
toler
viru
antigen
direct
deliveri
cytokin
suggest
probabl
addit
event
occur
liver
advmedi
transfer
support
antivir
effect
therapi
adenovir
deliveri
gene
cytokin
immunomodul
wide
use
cancer
therapi
anim
tumor
model
well
patient
cell
play
import
role
defens
pathogen
also
antitumor
immun
inhibit
tumor
growth
inhibit
angiogenesi
induc
potent
antitumor
immun
respons
stimul
secret
therefor
promis
candid
cancer
gene
therapi
strategi
base
recombin
adenovirus
express
demonstr
antitumor
effect
murin
model
transplant
hcc
also
evalu
woodchuck
studi
larg
cm
intrahepat
tumor
woodchuck
inject
singl
dose
pfu
adv
express
molecul
molecul
also
known
natur
express
profession
apc
provid
synergist
effect
tumor
regress
anim
deliv
laparotomi
three
hcc
nodul
three
nodul
inject
vector
express
gfp
control
anim
sacrif
day
later
tumor
volum
assess
averag
treat
tumor
show
reduct
volum
wherea
size
adgfpinject
nodul
increas
remiss
tumor
associ
cell
infiltr
tumor
tissu
increas
local
level
inject
one
treat
woodchuck
receiv
intratumor
inject
magnet
reson
imag
mri
guidanc
monitor
week
period
tumor
size
decreas
cm
cm
observ
show
administr
mri
guidanc
therapeut
effect
similar
laparotomi
could
prevent
anim
harm
consequ
surgeri
studi
prove
gene
therapi
base
lead
may
promis
strategi
treat
hcc
contrast
treatment
adv
encod
herp
simplex
thymidin
kinas
combin
gancclovir
administr
lead
reduct
tumor
size
nevertheless
short
time
monitor
studi
make
difficult
evalu
prolong
antitumor
effect
approach
recent
studi
present
gene
therapi
semliki
forest
viral
vector
express
high
level
murin
remiss
hcc
chronic
whvinfect
woodchuck
research
vector
deliv
surgeri
multipl
site
hcc
tumor
liver
total
nine
woodchuck
enrol
experi
six
woodchuck
two
anim
receiv
differ
dose
vp
vp
vp
three
anim
serv
control
receiv
salin
inject
tumor
size
monitor
ultrasound
examin
week
woodchuck
reduct
tumor
volum
observ
howev
effect
transient
dose
depend
anim
treat
highest
dose
show
spectacular
reduct
tumor
size
nevertheless
tumor
start
grow
week
treatment
antitumor
effect
associ
induct
immun
respons
toward
tumor
antigen
demonstr
cell
prolifer
assay
upregul
leukocyt
marker
express
cytokin
product
addit
therapi
result
transient
induct
lymphoprolif
respons
whcag
whsag
led
shortterm
reduct
whv
viral
load
result
present
indic
viralmedi
gene
therapi
treatment
chronic
hepat
b
hcc
need
optim
howev
treatment
woodchuck
viral
vector
allow
achiev
longlast
express
cytokin
higher
concentr
prefer
liver
therefor
strategi
proven
effect
approach
base
use
solubl
cytokin
addit
adenovirusmedi
gene
transfer
proven
safe
welltoler
strategi
woodchuck
current
progress
indic
feasibl
therapeut
approach
treatment
chronic
hbv
infect
gener
agreement
combin
antivir
treatment
immunomodul
essenti
achiev
sustain
control
hbv
infect
howev
mani
scientif
question
still
answer
question
hbv
infect
lead
defect
immun
respons
hbv
protein
remain
investig
issu
key
ration
design
new
therapeut
approach
recent
hbv
protein
found
suppress
host
innat
respons
clarifi
whether
earli
blockag
innat
immun
respons
may
neg
influenc
prime
adapt
immun
respons
addit
differ
group
report
consist
signal
may
impair
chronic
hbv
infect
patient
thu
worthi
test
whether
enhanc
innat
immun
respons
chronic
carrier
necessari
restor
specif
immun
respons
increas
number
avail
vaccin
formul
crucial
question
rais
recent
optim
combin
vaccin
obvious
necessari
test
mutual
influenc
differ
type
vaccin
maxim
effect
avoid
neg
interfer
vaccin
final
futur
design
therapeut
vaccin
need
consid
host
sinc
patient
undergon
infect
yet
possibl
forese
preexist
infect
immunolog
background
influenc
effect
therapeut
vaccin
understand
issu
help
translat
recent
progress
clinic
use
therapeut
vaccin
